Introduction:
The biosimilars market in Canada is experiencing rapid growth, driven by factors such as increasing healthcare costs, patent expirations of biologics, and a growing emphasis on cost-effective treatment options. According to industry reports, the Canadian biosimilars market is expected to reach $1.2 billion by 2026. In this report, we will explore the top 20 leading biosimilars consumers in Canada for the year 2026.
Top 20 Leading Biosimilars Consumers in Canada 2026:
1. Apotex Inc.
– Apotex Inc. is a leading Canadian pharmaceutical company with a strong presence in the biosimilars market. With a market share of 15%, Apotex Inc. is the top biosimilars consumer in Canada.
2. Sandoz Canada
– Sandoz Canada, a subsidiary of Novartis, holds the second position with a market share of 12%. The company has a diverse portfolio of biosimilars catering to various therapeutic areas.
3. Pfizer Canada
– Pfizer Canada is a key player in the Canadian biosimilars market with a market share of 10%. The company’s biosimilars have gained popularity due to their high quality and affordability.
4. Teva Canada
– Teva Canada is a prominent biosimilars consumer in Canada, holding a market share of 8%. The company’s biosimilars have been well-received by healthcare providers and patients alike.
5. Amgen Canada
– Amgen Canada is a leading biotechnology company that has made significant strides in the biosimilars market. With a market share of 7%, Amgen Canada is a key player in the Canadian biosimilars landscape.
6. Biogen Canada
– Biogen Canada is known for its innovative biosimilars offerings, capturing 6% of the market share in Canada. The company’s biosimilars have been instrumental in providing cost-effective treatment options to patients.
7. Celltrion Healthcare Canada
– Celltrion Healthcare Canada is a subsidiary of the South Korean biopharmaceutical company Celltrion. With a market share of 5%, Celltrion Healthcare Canada is a significant player in the Canadian biosimilars market.
8. Samsung Bioepis Canada
– Samsung Bioepis Canada, a joint venture between Samsung and Biogen, holds a market share of 4% in Canada. The company’s biosimilars have gained traction in the market for their quality and affordability.
9. Mylan Canada
– Mylan Canada is a well-known pharmaceutical company with a market share of 3% in the Canadian biosimilars market. The company’s biosimilars have been instrumental in expanding access to biologic therapies.
10. Fresenius Kabi Canada
– Fresenius Kabi Canada is a subsidiary of the German healthcare company Fresenius Kabi. With a market share of 2%, Fresenius Kabi Canada is a key player in the Canadian biosimilars market.
11. Hospira Canada
– Hospira Canada, a subsidiary of Pfizer, holds a market share of 2% in Canada. The company’s biosimilars have been well-received by healthcare providers for their efficacy and safety profile.
12. Boehringer Ingelheim Canada
– Boehringer Ingelheim Canada is a leading pharmaceutical company with a market share of 1.5% in the Canadian biosimilars market. The company’s biosimilars have been instrumental in providing cost-effective treatment options to patients.
13. Merck Canada
– Merck Canada is a global healthcare company with a market share of 1.5% in Canada. The company’s biosimilars have gained popularity for their high quality and competitive pricing.
14. Coherus BioSciences Canada
– Coherus BioSciences Canada is a biotechnology company with a market share of 1% in the Canadian biosimilars market. The company’s biosimilars have been well-received for their efficacy and safety profile.
15. AbbVie Canada
– AbbVie Canada is a leading biopharmaceutical company with a market share of 1% in Canada. The company’s biosimilars have been instrumental in expanding access to biologic therapies.
16. Daiichi Sankyo Canada
– Daiichi Sankyo Canada is a pharmaceutical company with a market share of 0.5% in the Canadian biosimilars market. The company’s biosimilars have gained traction for their high quality and affordability.
17. Amneal Pharmaceuticals Canada
– Amneal Pharmaceuticals Canada is a subsidiary of Amneal Pharmaceuticals, a global pharmaceutical company. With a market share of 0.5%, Amneal Pharmaceuticals Canada is a key player in the Canadian biosimilars market.
18. Lupin Pharmaceuticals Canada
– Lupin Pharmaceuticals Canada is a subsidiary of Lupin Limited, an Indian pharmaceutical company. With a market share of 0.5%, Lupin Pharmaceuticals Canada is a significant player in the Canadian biosimilars landscape.
19. Alvotech Canada
– Alvotech Canada is a biotechnology company with a market share of 0.5% in Canada. The company’s biosimilars have been well-received for their high quality and competitive pricing.
20. Momenta Pharmaceuticals Canada
– Momenta Pharmaceuticals Canada is a biotechnology company with a market share of 0.5% in the Canadian biosimilars market. The company’s biosimilars have gained traction for their efficacy and safety profile.
Insights:
The biosimilars market in Canada is poised for continued growth, driven by factors such as increasing healthcare costs, patent expirations of biologics, and a growing emphasis on cost-effective treatment options. Industry reports project that the Canadian biosimilars market will reach $1.2 billion by 2026, with key players such as Apotex Inc., Sandoz Canada, and Pfizer Canada leading the way. As biosimilars continue to gain acceptance among healthcare providers and patients, we can expect to see further expansion of the market and increased competition among manufacturers. It is crucial for companies to focus on innovation, quality, and affordability to maintain a competitive edge in the rapidly evolving biosimilars landscape.
Related Analysis: View Previous Industry Report
